ReviewBlood advances2018

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Ajai Chari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.